Policy experts predict obesity drugs' impact on Medicare

A group of health policy strategists wrote in The New England Journal of Medicine that caution is needed when considering whether Medicare should cover obesity drugs such as Novo Nordisk's Wegovy, which have shown a high level of effectiveness in helping people lose weight. They point out that there would be a significant cost burden for Medicare, which likely would lead to premium hikes, and they also note that the drugs may offer a less desirable risk-benefit balance for older people than for other age groups.

Read the full story in STAT